| Literature DB >> 33946899 |
Francesco Ardito1,2, Francesco Razionale1, Lisa Salvatore3, Tonia Cenci4, Maria Vellone1,2, Michele Basso3, Elena Panettieri1, Maria Alessandra Calegari3, Giampaolo Tortora2,3, Maurizio Martini4, Felice Giuliante1,2.
Abstract
If KRAS mutation status of primary colorectal tumor is representative of corresponding colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess the incidence of discordance and its impact on overall survival (OS) in a homogenous group of patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate was 15.9%. Its incidence varied according to the time interval between the two mutation analyses (p = 0.025; Pearson correlation = 0.2) and it was significantly higher during the first 6 months from the time of primary tumor evaluation. On multivariable analysis, type of discordance (wild-type in primary tumor, mutation in CRLM) was the strongest predictor of poor OS (p < 0.001). At multivariable logistic regression analysis, the number of CRLM >3 was an independent risk factor for the risk of KRAS discordance associated with the worst prognosis (OR = 4.600; p = 0.047). Results of our study suggested that, in the era of precision medicine, possibility of KRAS discordance should be taken into account within multidisciplinary management of patients with metastatic colorectal cancer.Entities:
Keywords: KRAS discordance; KRAS mutation status; colorectal liver metastases; colorectal tumor; overall survival; precision medicine
Year: 2021 PMID: 33946899 DOI: 10.3390/cancers13092148
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639